Regeneron Pharmaceuticals (REGN) had its best quarter since 2019 in Q4 2019, returning 35.4%.

ASSET	QUARTER	% RETURN
Regeneron Pharmaceuticals (REGN)	Q1 2019	11.54%
Regeneron Pharmaceuticals (REGN)	Q2 2019	-24.12%
Regeneron Pharmaceuticals (REGN)	Q3 2019	-12.66%
Regeneron Pharmaceuticals (REGN)	Q4 2019	35.42%
Regeneron Pharmaceuticals (REGN)	Q1 2020	29.18%
Regeneron Pharmaceuticals (REGN)	Q2 2020	28.82%
Regeneron Pharmaceuticals (REGN)	Q3 2020	-10.44%
Regeneron Pharmaceuticals (REGN)	Q4 2020	-14.11%
Regeneron Pharmaceuticals (REGN)	Q1 2021	-2.82%
Regeneron Pharmaceuticals (REGN)	Q2 2021	18.33%
Regeneron Pharmaceuticals (REGN)	Q3 2021	8.73%
Regeneron Pharmaceuticals (REGN)	Q4 2021	9.5%
Regeneron Pharmaceuticals (REGN)	Q1 2022	11.75%
Regeneron Pharmaceuticals (REGN)	Q2 2022	-15.77%
Regeneron Pharmaceuticals (REGN)	Q3 2022	17.2%
Regeneron Pharmaceuticals (REGN)	Q4 2022	2.28%
Regeneron Pharmaceuticals (REGN)	Q1 2023	13.83%
Regeneron Pharmaceuticals (REGN)	Q2 2023	-12.24%
Regeneron Pharmaceuticals (REGN)	Q3 2023	15.9%
Regeneron Pharmaceuticals (REGN)	Q4 2023	6.2%
Regeneron Pharmaceuticals (REGN)	Q1 2024	10.14%
Regeneron Pharmaceuticals (REGN)	Q2 2024	8.95%
Regeneron Pharmaceuticals (REGN)	Q3 2024	0.39%
Regeneron Pharmaceuticals (REGN)	Q4 2024	-32.42%
Regeneron Pharmaceuticals (REGN)	Q1 2025	-11.9%